search icon
      blog search icon

      Oragenics, Inc. (OGEN) stock rises in Intraday trading: What’s Going on? - Stocks Telegraph

      By Muhammad Ali

      Published on

      August 30, 2021

      2:25 PM UTC

      Oragenics, Inc. (OGEN) stock rises in Intraday trading: What’s Going on? - Stocks Telegraph

      Oragenics, Inc. (OGEN) stock rose today after it announced the recent update of SARS-CoV-2 Spike Protein. OGEN stock became green and saw a push of 6.39% to reach $0.72 a share at the time of this writing. The stock was gloomy in the previous trade and went down by 2.67% at closing. Let’s deep dive to explore the recent events in detail.

      What’s Happening?

      Oragenics, Inc. is the developer of therapeutics to treat infectious diseases in the United States of America. The stock recently announced the new data of its SARS-CoV-2 stabilized pre-fusion spike protein trimer. OGEN stock’s Canadian collaborator has developed this protein and the National Institutes of Health licensed it. The protein when administrated with several novel intramuscular (IM) and intranasal (IN) adjuvants, generated neutralizing antibodies in mice after immunization against SARS-CoV-2.  The expression platform will soon evaluate hybrid SARS-CoV-2 antigen candidates in a hamster viral challenge study.  The mouse immunogenicity study has enabled the study team to down select its four tested adjuvant candidates so far.

      OGEN stock Postpones Shareholders Annual Meeting:

      Last week Oragenics announced that its reconvened shareholder’s meeting on August 23, 2021, was postponed due to lack of quorum. OGEN stock is intending to get shareholders’ approvals for its submitted proposal. The company will announce the new date of the annual meeting.

      OGEN stock Enters Licensing Agreement with National Research Council of Canada:

      Oragenics stock signed licensing agreement with the National Research Council (NRC) of Canada In the last week of July 2021. This agreement will help OGEN stock for the speedy development of next-generation vaccines against the SARS-CoV-2 virus and its variants. The NRC technologies along with the U.S. National Institutes of Health have provided the platform to OGEN stock for high-yield cell production of spike protein antigens. According to the report, the platform will ensure cell line production within 6 to 8 weeks of spike gene sequence availability. This compares to the traditional cell line production period of six to nine months.

      Conclusion:

      OGEN stock became green after the recent announcement as investors are responding positively in the stock market. The stock has now positioned itself well but it would be interesting to see how long this bullish trend persists.

      More From Stocks telegraph